Werewolf Therapeutics, Inc. Common Stock (HOWL)

Price$0.47

Value ScoreB

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-63.28%

Price vs S&P 500 (4W)-42.73%

VGM Score50.04

Market Capitalization$21.87M

All Metrics

Book Value / Share (Quarterly)$0.25

P/TBV (Annual)0.71x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.07

Price vs S&P 500 (YTD)-39.90%

Net Profit Margin (TTM)-578.67%

EPS (TTM)$-1.21

10-Day Avg Trading Volume0.61M

EPS Excl Extra (TTM)$-1.21

EPS (Annual)$-1.32

ROI (Annual)-114.67%

Cash / Share (Quarterly)$0.96

ROA (Last FY)-87.64%

EBITD / Share (TTM)$-1.16

ROE (5Y Avg)-90.31%

Operating Margin (TTM)-634.15%

Cash Flow / Share (Annual)$-1.24

P/B Ratio1.79x

P/B Ratio (Quarterly)3.32x

Net Income / Employee (Annual)$-1,559,500

EV / Revenue (TTM)0.46x

Net Interest Coverage (TTM)-27.08x

ROA (TTM)-75.12%

EPS Incl Extra (Annual)$-1.32

Current Ratio (Annual)1.62x

Quick Ratio (Quarterly)1.21x

3-Month Avg Trading Volume0.46M

52-Week Price Return-64.84%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.15

P/S Ratio (Annual)11.60x

Asset Turnover (Annual)0.01x

52-Week High$2.38

EPS Excl Extra (Annual)$-1.32

CapEx CAGR (5Y)-1.21%

26-Week Price Return-47.35%

Quick Ratio (Annual)1.58x

13-Week Price Return-28.79%

Total Debt / Equity (Annual)1.14x

Current Ratio (Quarterly)1.27x

Enterprise Value$4.25M

Asset Turnover (TTM)0.05x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-3740.85%

Cash / Share (Annual)$1.17

3-Month Return Std Dev97.49%

Net Income / Employee (TTM)$-1,442,700

ROE (Last FY)-245.20%

Net Interest Coverage (Annual)-18.85x

EPS Basic Excl Extra (Annual)$-1.32

Receivables Turnover (TTM)5.04x

Total Debt / Equity (Quarterly)2.36x

EPS Incl Extra (TTM)$-1.21

ROI (TTM)-102.34%

P/S Ratio (TTM)2.35x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.89

Price vs S&P 500 (52W)-93.05%

Year-to-Date Return-28.97%

5-Day Price Return1.44%

EPS Normalized (Annual)$-1.32

ROA (5Y Avg)-45.21%

Net Profit Margin (Annual)-3740.85%

Month-to-Date Return-37.47%

Cash Flow / Share (TTM)$-1.04

EBITD / Share (Annual)$-1.28

Operating Margin (Annual)-3933.53%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-57.41%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.21

P/TBV (Quarterly)0.78x

P/B Ratio (Annual)1.24x

Pretax Margin (TTM)-578.67%

Book Value / Share (Annual)$0.51

Price vs S&P 500 (13W)-38.53%

Beta0.27x

Revenue / Share (TTM)$0.00

ROE (TTM)-208.23%

52-Week Low$0.40

vGradeB

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.28est. -0.29

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.17

4.27

4.20

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
HOWLWerewolf Therapeutics, Inc. Common Stock	B	—	D	$0.47
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Werewolf Therapeutics develops cancer immunotherapies using its proprietary PREDATOR platform to engineer conditionally activated molecules. The company's INDUKINE molecules remain inactive in healthy tissue but selectively activate immune responses within the tumor microenvironment, potentially addressing the side-effect limitations of conventional immunotherapies. This targeted approach aims to combine improved therapeutic efficacy with reduced systemic toxicity.